"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Remnant of a tumor or cancer after primary, potentially curative therapy.
| Descriptor ID |
D018365
|
| MeSH Number(s) |
C04.697.700 C23.550.727.700
|
| Concept/Terms |
Neoplasm, Residual- Neoplasm, Residual
- Residual Neoplasms
- Residual Neoplasm
- Minimal Residual Disease
- Minimal Disease, Residual
- Residual Minimal Disease
- Residual Minimal Diseases
- Residual Disease, Minimal
- Minimal Residual Diseases
Residual Tumor- Residual Tumor
- Residual Tumors
- Residual Tumour
- Residual Tumours
- Tumour, Residual
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".
This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 3 | 3 |
| 2016 | 0 | 4 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2021 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Intraoperative 3?T MRI is more correlative to residual disease extent than early postoperative MRI. J Neurooncol. 2021 Sep; 154(3):345-351.
-
Prognostic factors for residual occult disease in shave margins during partial mastectomy. Breast Cancer Res Treat. 2021 Sep; 189(2):471-481.
-
Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. J Clin Oncol. 2021 05 10; 39(14):1540-1552.
-
Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. Biol Blood Marrow Transplant. 2018 10; 24(10):2040-2046.
-
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018 Jun; 210(6):1376-1385.
-
5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins. Sci Rep. 2017 Nov 15; 7(1):15593.
-
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
-
Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Dec; 143(3):511-515.
-
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
-
Impact of adjuvant chemoradiation on survival in patients with resectable cholangiocarcinoma. HPB (Oxford). 2016 10; 18(10):843-850.